KWM
IMRX icon

Kingsview Wealth Management’s Immuneering IMRX Stock Holding History

Kingsview Wealth Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Buy
122,200
+3,600
+3% +$18.5K 0.01% 817
2025
Q4 		$780K Buy
118,600
+28,600
+32% +$184K 0.01% 705
2025
Q3 		$630K Buy
90,000
+76,000
+543% +$394K 0.01% 733
2025
Q2 		$47.2K Buy
+14,000
New +$24K ﹤0.01% 1152

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kingsview Wealth Management's IMRX Position: Q1 2026 in Review

Kingsview Wealth Management increased its Immuneering (IMRX) stake by 3% in Q1 2026, buying an estimated $18.5K and bringing the position to 122,200 shares worth $644K. The position accounts for 0.01% of the portfolio, ranked #817.

Kingsview Wealth Management first reported a position in IMRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $780K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Kingsview Wealth Management held 122,200 shares of Immuneering worth $644K as of Q1 2026.
  • Kingsview Wealth Management bought 3,600 Immuneering shares in Q1 2026, an estimated $18.5K.
  • Immuneering made up 0.01% of Kingsview Wealth Management's portfolio in Q1 2026, its #817 holding.
  • Kingsview Wealth Management first reported a position in Immuneering in Q2 2025 and has held it in 4 quarters since.
  • Kingsview Wealth Management's Immuneering position peaked at $780K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.